Intas Pharmaceuticals

In 1977, a Jain pharmacist in Ahmedabad started a pharmaceutical company aimed at the part of the chronic-therapy market that combined patient affordability with international quality discipline. Hasmukh Chudgar incorporated Intas Pharmaceuticals in 1985, and his three sons (Binish, Nimish and Urmish) took the operating roles in the early 1990s. Today the family owns about 83.85 percent of the business, with Temasek Holdings and ChrysCapital holding the institutional minorities.

Two engines, one private company

Intas' commercial signature is a paired engine: an Indian branded chronic-care business (cardio-metabolic, CNS, oncology) and a regulated-market generics franchise carried by London-headquartered Accord Healthcare across the UK, EU and US. The European franchise was unlocked in 2007 when Intas became the first Indian manufacturer to receive EU GMP certification. In 2015 the group launched Filgrastim, its first biosimilar, in Europe. The defining moves came in 2016 and 2017: Accord acquired Teva's UK and Ireland generics business for about US$764 million in 2016, then acquired Actavis UK and Ireland from Teva at an enterprise value of about £603 million in 2017. The pair of deals took Intas into the global top-20 generic players club and made Accord one of the larger generic companies in the UK and Ireland.

The biopharmaceutical arm, originally Intas Biopharmaceuticals (incorporated 2000), was merged with the parent in 2012 to 2013. It develops and manufactures biosimilars based on recombinant DNA and monoclonal antibodies; the third operating track alongside India branded and Accord regulated-market generics.

Why the commercial engine is the interesting part

By FY2025 Intas reports revenue of about ₹21,200 crore on net income of about ₹1,522 crore, with 25,000-plus employees and 22 manufacturing plants. About 69 percent of revenue came from international markets per FY2019 disclosures; the international share has stayed material since. The operating reality is that three engines run on different cadences inside a single private-company structure: Indian branded chronic care depends on rep coverage, specialist relationships and divisional discipline; Accord depends on tender wins, hospital formularies and pricing discipline in price-erosion-heavy regulated markets; and biosimilars depend on multi-year clinical and regulatory milestones.

A December 2022 US FDA inspection at the Sanand plant documented data-integrity issues, including destruction of test records. The remediation work that followed is, mechanically, part of the group's current operating reality. Quality and regulatory discipline at multinational scale is no longer a supporting function; it is on the critical path next to commercial growth.

The next chapter

The next chapter is less about adding engines and more about coordinating the three already in motion. Accord's UK, EU and US franchise needs the European tender book and US filings cadence to compound. The biosimilars track needs to translate filings into commercial scale outside the legacy Filgrastim line. The Indian branded chronic-care business needs to keep its specialist relationships sharp as competitive intensity rises. The 2022 Sanand observations are a reminder that the cost of a quality slip in any one of these engines is borne by the others.

It will not be more dashboards. The next advantage is intelligence: every Indian chronic-care rep walking in already knowing what shifted in this specialist's prescribing this fortnight, every Accord commercial team in the UK or Germany separating a tender-channel slip from a formulary one in time to act, every quality-systems lead spotting recurring lab deviation patterns within the week rather than the quarter, every leadership review focused on the few cross-engine decisions that actually move the year. The first generation of Indian pharma built access. The second built scale. The next will build intelligent commercial operations. That is the future PharmaOS is built for.